

Client: Avesthagen
Source: Bioworld Financial Watch
Date: 12 February 2007
Page: 19
Circulation: 0
Size: 265cm2
AVE: 1484

Venture Capital And Other Investments In Private Biotechnology Companies: January 2007

FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: \$518.65M

Company	Location	Date	Amt. (M)	Details
4-Antibody AG	Basel, Switzerland	1/16/07	CHF17 (US\$13.6)	4-Antibody raised CHF17M in its Series A round led by Advent Venture Partners; other investors were Biomedinvest AG, Grazia Equity GmbH, Life Sciences Partners and Mulligan Biocapital AG, as well as several private investors
Althea Technologies Inc.	San Diego	1/9/07	\$23	Investing in the Series C financing investment were funds managed by Telegraph Hill Partners
Avesthagen Pvt. Ltd.	Bangalore	1/31/07**	€25 (US\$32.3)	Investors in the round included Fidelity International, Limagrain Group, Daninvest and Bennett Coleman
Ception Therapeutics Inc.	Malvern, Pa.	1/30/07	\$63	Series C round was led by Essex Woodlands Health Ventures and included participation by Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture Venture Partners
Conatus Pharmaceuticals Inc.	San Diego	1/3/07	\$5.5	Conatus closed on the the first \$5.5M in what was expected to be a \$27.5M financing round; the round was led by Aberdare Ventures, and included Advent Venture Partners, Bay City Capital and Gilde Healthcare Partners